Inhibición de la proliferación celular de la línea B16-10 por la región extracelular del receptor de IL-10 recombinante
Contenido principal del artículo
Resumen
Las citocinas son proteínas pequeñas secretadas por diversas células, tienen diversas funciones, entre otras, induc- ción del crecimiento y diferenciación celular, actividades citolíticas, apoptosis y quimiotaxis, Los términos linfocinas o monocinas, utilizados en el área inmunológica, sirven para designar el origen celular de la citocinas.
Detalles del artículo
Sección
Cómo citar
Referencias
Dumonde DC, Wolstencroft RA, Panayi GS, Matthew M, Morley J, Howson WT. Lymphokines: non-antibody mediators of cellular immunity generated by lymphocyte action. Nature 1969; 224: 38.
Cohen S, Bigazzi PE, Yoshida T. Commentary. Similarities of T cell function in cell-mediated immunity and antibody production. Cell Immunol 1974; 12: 150.
Oppenheim JJ, Gery I. From lymphodrek to interleukin 1 (IL- 1). Immunol Today 1993; 14: 232.
Darnell JE Jr. The JAK-STAT pathway: summary of initial studies and recent advances. Recent Prog Horm Res 1996; 51: 391.
Mosmann TR, Cherwinski H, Bond HW, Giedlin MA, Cosff-man RL. J Immunol 1986; 136: 2348-57.
Mosmann TR, Coffman RL. Annu Rev Immunol 1989; 7: 145-73.
Romagnani S. Biology of human TH1 and TH2 cells. J Clin Immunol 1995; 15: 121-9.
Bazan JF. Shared architecture of hormone binding domains in type I and type II interferon receptors. Cell 1990: 61: 753.
Sprang SR, Bazan JF. Cytokine structural taxonomy and me- chanisms of receptor engagement. Curr Opin Struc Biol 1993; 3: 815.
Nicola NA. Annu Rev Biochem 1989; 58: 45-77.
Ihle JN. STATs: signal transducers and activators of trans- cription. Cell 1996; 84: 331.
Leonard WJ. Stats and cytokine specificity. Nature Med 1996; 2: 968.
Briscoe J, Rogers NC, Witthuhn BA, et al. Kinase-negative mutants of JAK1 can sustain interferon-g inducible gene expression but not an antiviral state. EMBO J 1996; 15: 799.
Darnel JE Jr, Kerr IM, Stark GR, Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415.
Wilks AF, Oates AC. The JAK/STAT pathway. Cancer Surv 1996; 27: 139.
Leonard WJ. Stats and cytokine specificity. Nature Med 1996; 2: 968.
Leonard WJ, Oshea JJ. Jaks and STATS: biological implicatio- ns. Annu Rev Immunol 1998; 16: 293-322.
Decker T, Kovarik P. Transcription factor activity of STAT proteins: structural requirements and regulation by phos- phorylation and interacting proteins. Cell Mol Life Sci 1999; 55: 1535-46.
Darnell JE Jr. STATs and gene regulation. Science (Wach. DC) 1997; 277: 1630-5.
Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000; 19: 6613-6626.
García R, Jove R. Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J Biomed Sci 1998; 5: 79-85.
Catlett-Falcone R, Dalton WS, Jove R. STAT proteins as novel targets for cancer therapy. Signal transducer and activator of transcription. Curr Opin Oncol 1999; 11: 490-6.
Bowman T, García R, Turkson J, Jove R. STATs in oncogene- sis. Oncogene 2000; 19: 2474-88.
Garcia R, Jove R. Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J Biomed Sci 1998; 5: 79-85.
García R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A, Jove R. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regula- tion of human breast carcinoma cells. Oncogene 2001; 20: 2499- 513.